Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) är en konsultgrupp inom samhällsbyggnad, vilka...
Nettoomsättningen kom in åt det svagare hållet men resultatet förbättrades, drivet av ökade licensin...
Redeye comments on BONESUPPORT’s CEO change announced yesterday.
Orders +7%, sales -1%, adj. EBITA +28% vs. our estimates Key takeaway is the continued order strengt...
Q1 sales +11% y-o-y coupled with improving margins We cut '25e-'26e adj.
Sales in line with ABGSCe, ARR slightly below Limited, downward consensus estimate revisions Highlig...
Sales +29%, adj. EBITA +20%, +29% org. growth '25e-'27e EBITA estimates to increase by 1-3% Share to...
Adj. EBITA -12% vs cons, but organic growth better Est's down 3-4%, but better growth outlook mainta...
Redeye is encouraged to see solid financial performance in Q1, showing good growth, improving gross ...
Redeye provides an initial comment on the Q1 2025 report from Tradedoubler.
Sales 1% below cons, adj. EBITA in line with cons Consensus EBITA estimate revisions flat to slightl...
Redeye comments on Formpipe’s Q1 report showing an ACV and EBITDA – CAPEX roughly matching our expec...
The 12-month safety results confirm and extend the earlier results after 3 months, adding support bo...
CEO Rikard Fröberg gives a short introduction of his background and his plans for Hexatronic.
Redeye provides its first take on Cellavision’s Q1 report 2025, published this morning.
Redeye believes Sdiptech's Q1 report was solid despite a drop in organic sales and adjusted EBITA wh...
8%/9% adj. EBITDA vs ABGSCe/cons in Q1 Cons estimates likely up low to mid single digits on adj.
Redeye comments on SHH´s Q1 2025. SSH posted a growth of 8% Y/Y slightly lower than our estimate.
With the increased number of active centers, the complete enrolment of the European PAES study, and ...
